Press

  • Eisai Licenses EpiVax's ISPRI Toolkit for Preclinical in silico Immunogenicity Screening

    Eisai Licenses EpiVax’s ISPRI Toolkit for Preclinical in silico Immunogenicity Screening

    Posted on December 20, 2023 by Elena Iemma
    The ISPRI toolkit is a secure web-based platform that allows researchers to rapidly assess the immunogenic risk of biologic candidates. The fully integrated computational immunology toolkit can be used to identify sequence regions that could elicit unwanted immune responses and enables developers to re-engineer early-stage candidates to reduce risk. Most notably, ISPRI allows developers to ...
    Read more
  • EpiVax CEO Speaks at the Hwasun International Vaccine and Immunotherapy Forum

    EpiVax CEO Speaks at the Hwasun International Vaccine and Immunotherapy Forum

    Posted on November 20, 2023 by Elena Iemma
    EpiVax CEO Speaks at the Hwasun International Vaccine and Immunotherapy Forum
    Read more
  • Streamlining Generic Drug Immunogenicity Evaluation:  EpiVax’s "PANDA" Approach

    Streamlining Generic Drug Immunogenicity Evaluation: EpiVax’s “PANDA” Approach

    Posted on August 10, 2023 by Elena Iemma
    EpiVax Inc. announces the publication of results from a research collaboration with the Food and Drug Administration aimed at streamlining generic drug evaluations. The research, initiated in 2018 with a $1M contract spanning two years (HHSF223018186C), was established to develop best practices for assessing the immunogenic potential of active pharmaceutical ingredients and their impurities for ...
    Read more
  • Providence-based "Biotech start up" EpiVax Celebrates 25th Anniversary

    Providence-based “Biotech start up” EpiVax Celebrates 25th Anniversary

    Posted on May 17, 2023 by Elena Iemma
    EpiVax is celebrating its 25th birthday by renewing the company’s commitment to improving human health everywhere while highlighting the development of groundbreaking tools by the company.
    Read more
  • EpiVax: 25 years of Fearless Science

    EpiVax: 25 years of Fearless Science

    Posted on May 16, 2023 by Elena Iemma
    EpiVax is celebrating 25 years of innovative immunoinformatics tool development. The company’s mission is to improve the safety and efficacy of vaccines and protein therapeutics, while working to improve human health everywhere. 1998  EpiVax Founded by Dr. Annie De Groot and Mr. Bill Martin Following years of training in internal medicine, immunology, immunoinformatics, and vaccinology, ...
    Read more
  • EpiVax and Zoetis to Collaborate on Swine T cell Epitope Prediction Tool: CircoMatch™

    EpiVax and Zoetis to Collaborate on Swine T cell Epitope Prediction Tool: CircoMatch™

    Posted on January 10, 2023 by Sameer Laul
    PROVIDENCE, RI, January 10, 2023 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) and Zoetis, are pleased to announce an exclusive collaboration to develop CircoMatch™, a unique bioinformatics tool that predicts the coverage of Porcine Circovirus Type 2 (PCV2) vaccines against field isolates of PCV2. The new tool provides a quick turnaround, powerful way to provide near real-time ...
    Read more
  • EpiVax, Inc. Subsidiary, EpiVax Therapeutics Signs Exclusive Collaboration Agreement with GreenLight Biosciences to Develop Personalized Cancer Vaccines

    Posted on January 9, 2023 by Sameer Laul
    EpiVax, Inc. is excited to announce that its subsidiary, EpiVax Therapeutics, has signed an exclusive collaboration agreement with GreenLight Biosciences to advance the development of personalized cancer vaccines.   The effort will combine GreenLight’s mRNA design and manufacturing expertise with EpiVax’s advanced Ancer® pipeline for personalized cancer vaccine design Epivax Therapeutics, Inc. will contribute a proprietary set of ...
    Read more
  • #VaxGivesBack and 2022 Charitable Giving

    #VaxGivesBack and 2022 Charitable Giving

    Posted on January 6, 2023 by Sameer Laul
    “I have found that among its other benefits, giving liberates the soul of the giver.” – Maya Angelou EpiVax’s VaxGivesBack Fund kicked the holiday off by partnering with AIDS Care Ocean State  and Clinica Esperanza/Hope Clinic to distribute gifts to local families. Pictures of the gift giveaway at CEHC last weekend are linked here. This is the 4th ...
    Read more
  • EpiVax Joins Intravacc, CEPI on Project to Develop Universal Betacoronavirus Vaccine

    EpiVax Joins Intravacc, CEPI on Project to Develop Universal Betacoronavirus Vaccine

    Posted on October 31, 2022 by Riley Nolan
    EpiVax Joins Intravacc, CEPI on Project to Develop Universal Betacoronavirus Vaccine PROVIDENCE, RI, October 31, 2022 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is pleased to announce participation in a new project with Intravacc, funded by CEPI (Coalition for Epidemic Preparedness Innovations), to develop universal vaccines for betacoronaviruses, including SARS-CoV-2. EpiVax will be carrying out the vaccine epitope ...
    Read more
  • EpiVax Secures Additional Funding from FDA for Immunogenicity Risk Assessment for Biosimilar Products

    EpiVax Secures Additional Funding from FDA for Immunogenicity Risk Assessment for Biosimilar Products

    Posted on September 12, 2022 by Riley Nolan
    PROVIDENCE, RI, September 12, 2022 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is pleased to announce the award of a two-year, $2 million grant from the FDA’s Office of Center for Drug Evaluation and Research (CDER) to validate a method for immunogenicity risk assessment of host cell proteins (HCP) for improving biosimilar product development and assessing product ...
    Read more
  • EpiVax Poxvirus Vaccine Candidate Predicted to be Effective Against Monkeypox

    EpiVax Poxvirus Vaccine Candidate Predicted to be Effective Against Monkeypox

    Posted on June 10, 2022 by Riley Nolan
    PROVIDENCE, RI, June 10, 2022 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces that it has developed VennVax, a smallpox vaccine candidate that is predicted to be highly effective against monkeypox. The development of this vaccine was funded by the National Institutes of Health (SBIR grant #R43AI058376). The company is looking for a strategic partner with funding ...
    Read more
  • EpiVax and Massachusetts General Hospital Advance on T cell-Targeted Epitope Vaccine for Q Fever

    EpiVax and Massachusetts General Hospital Advance on T cell-Targeted Epitope Vaccine for Q Fever

    Posted on May 25, 2022 by Riley Nolan
    PROVIDENCE, RI, May 25, 2022 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces the publication “Evaluation of a Human T Cell-Targeted Multi-Epitope Vaccine for Q Fever in Animal Models of Coxiella burnetii Immunity” in Frontiers in Immunology, a collaboration with Massachusetts General Hospital’s (“MGH”) Vaccine and Immunotherapy Center, the Oxford Vaccine Group, Colorado State University, and Innatoss ...
    Read more
  • EpiVax Partners with Rhode Island Foundation to Expand Charitable Giving Programs

    EpiVax Partners with Rhode Island Foundation to Expand Charitable Giving Programs

    Posted on February 8, 2022 by Riley Nolan
    PROVIDENCE, RI, February 8, 2022 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces the establishment of the Vax Gives Back Fund at the Rhode Island Foundation, a step to continue the strong tradition of corporate responsibility and community service at the company. EpiVax has a long standing commitment to charitable giving since the company’s inception in 1998. Dr. ...
    Read more
  • EpiVax Progresses on a Vaccine to Address SARS-CoV-2 Variants

    EpiVax Progresses on a Vaccine to Address SARS-CoV-2 Variants

    Posted on November 30, 2021 by Riley Nolan
    PROVIDENCE, RI, November 30, 2021 /PRNewswire/ — Today EpiVax, Inc. (“EpiVax”) confirmed that the company’s EPV-CoV-19 vaccine epitope sequences are 98.2% conserved in the new Omicron SARS-CoV-2 variant. EpiVax and EpiVax Therapeutics, Inc. (“EVT”) are also affirming commitment to move the novel T cell epitope vaccine into the clinic in 2022. EPV-CoV-19, is intended for ...
    Read more
  • EpiVax Collaborates with Leidos on Malaria Vaccine Research, Series of Papers Published in Frontiers In Immunology

    EpiVax Collaborates with Leidos on Malaria Vaccine Research, Series of Papers Published in Frontiers In Immunology

    Posted on November 17, 2021 by Riley Nolan
    PROVIDENCE, RI, November 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces the publication of three papers focusing on malaria vaccine efficacy, part of a collaboration with Leidos, the University of Georgia Center for Vaccines and Immunology, the University of Oxford’s Jenner Institute, and Sanofi Pasteur’s VaxDesign Campus.  The work was supported by the Office of Infectious ...
    Read more

Join our newsletter

We strive to provide our clients, collaborators and everyday immunology enthusiasts with valuable content.  Written by our CEO/CSO Dr. Anne Dr Groot, you can expect up to date vaccine development efforts, upcoming events and so much more from our offices here in Providence, RI.

Click Here